

Dementia: assessment, management and support for people living with dementia and their carers



Consultation on draft guideline – deadline for comments 5pm on 12/02/2018 email: Dementia@nice.org.uk

	<p>Please read the checklist for submitting comments at the end of this form. We cannot accept forms that are not filled in correctly.</p> <p>We would like to hear your views on the draft recommendations presented in the short version and any comments you may have on the evidence presented in the full version. We would also welcome views on the Equality Impact Assessment.</p> <p>We would like to hear your views on these questions:</p> <ol style="list-style-type: none">1. Which areas will have the biggest impact on practice and be challenging to implement? Please say for whom and why.2. Would implementation of any of the draft recommendations have significant cost implications?3. What would help users overcome any challenges? (For example, existing practical resources or national initiatives, or examples of good practice.)4. [Insert any specific questions about the recommendations from the Developer, or delete if not needed] <p>See section 3.9 of Developing NICE guidance: how to get involved for suggestions of general points to think about when commenting.</p>
<p>Organisation name – Stakeholder or respondent (if you are responding as an individual rather than a registered stakeholder please leave blank):</p>	<p>British HIV Association</p>

Please return to: Dementia@nice.org.uk

Dementia: assessment, management and support for people living with dementia and their carers



Consultation on draft guideline – deadline for comments 5pm on 12/02/2018 email: Dementia@nice.org.uk

Disclosure Please disclose any past or current, direct or indirect links to, or funding from, the tobacco industry.		Nothing to declare		
Name of commentator person completing form:		Prof Brian Angus		
Type		[office use only]		
Comment number	Document (full version, short version or the appendices)	Page number Or 'general' for comments on the whole document	Line number Or 'general' for comments on the whole document	Comments Insert each comment in a new row. Do not paste other tables into this table, because your comments could get lost – type directly into this table.
Example 1	Full	16	45	We are concerned that this recommendation may imply that
Example 2	Full	16	45	Question 1: This recommendation will be a challenging change in practice because
Example 3	Full	16	45	Question 3: Our trust has had experience of implementing this approach and would be willing to submit its experiences to the NICE shared learning database. Contact.....
1	short	16	26	Regarding the use of memantine and AChE drugs, we are concerned that this recommendation may result in adverse drug interactions with antiretroviral drugs. Tenofovir DF increases levels of memantine by decreasing renal clearance and should be used with caution. Ritonavir will increase the level or effect of donepezil by affecting hepatic/intestinal enzyme CYP3A4. Ritonavir will increase the level or effect of galantamine by affecting hepatic/intestinal enzyme

Please return to: Dementia@nice.org.uk

Dementia: assessment, management and support for people living with dementia and their carers



Consultation on draft guideline – deadline for comments 5pm on 12/02/2018 email: Dementia@nice.org.uk

				CYP2D6.
2	Short	16	10	We are concerned that this recommendation does not include testing for HIV or referral to HIV specialist services. HIV is a potentially reversible cause of dementia.

Insert extra rows as needed

Checklist for submitting comments

- Use this comment form and submit it as a Word document (not a PDF).
- Complete the disclosure about links with, or funding from, the tobacco industry.
- Include page and line number (not section number) of the text each comment is about.
- Combine all comments from your organisation into 1 response. We cannot accept more than 1 response from each organisation.
- Do not paste other tables into this table – type directly into the table.
- Underline and highlight any confidential information or other material that you do not wish to be made public.
- Do not include medical information about yourself or another person from which you or the person could be identified.
- Spell out any abbreviations you use
- For copyright reasons, comment forms do not include attachments such as research articles, letters or leaflets (for copyright reasons).
We return comments forms that have attachments without reading them. The stakeholder may resubmit the form without attachments, but it must be received by the deadline.

You can see any guidance that we have produced on topics related to this guideline by checking [NICE Pathways](#).

Note: We reserve the right to summarise and edit comments received during consultations, or not to publish them at all, if we consider the comments are too long, or publication would be unlawful or otherwise inappropriate.

Comments received during our consultations are published in the interests of openness and transparency, and to promote understanding of how recommendations are developed. The comments are published as a record of the comments we received, and are not endorsed by NICE, its officers or advisory Committees.

Please return to: Dementia@nice.org.uk